Literature DB >> 15618720

Bioinformatics research on inter-racial difference in drug metabolism II. Analysis on relationship between enzyme activities of CYP2D6 and CYP2C19 and their relevant genotypes.

Takako Shimizu1, Hirohide Ochiai, Fredrik Asell, Yoshiya Yokono, Yoshiharu Kikuchi, Masashi Nitta, Yoshimasa Hama, Shizuyo Yamaguchi, Munehiro Hashimoto, Katsuhiko Taki, Kotoko Nakata, Yoshitaka Aida, Akira Ohashi, Naoki Ozawa.   

Abstract

The enzyme activities of CYP2D6 and CYP2C19 show a genetic polymorphism, and the frequency of poor metabolizers (PMs) on these enzymes depends on races. We have analyzed frequencies of mutant alleles and PMs based on the published data in previous study (Shimizu, T. et al.: Bioinformatics research on inter-racial difference in drug metabolism, I. Analysis on frequencies of mutant alleles and poor metabolizers on CYP2D6 and CYP2C19.). The study shows that there were racial differences in the frequencies of each mutant allele and PMs. In the present study, the correlation between genotypes and drug-metabolizing enzyme activities was investigated. The result showed that enzyme activities varied according to the genotypes of subjects even in the same race. On the other hand, if subjects had the same genotypes, almost no racial differences were observed in drug-metabolizing enzyme activities. From these results, it was supposed that the racial differences in activities of these enzymes could be explained by the differences in distribution of genotypes. It would be possible to explain the racial differences in drug-metabolizing enzyme activities based on the differences on individual pharmacogenetic background information, not merely by comparison of frameworks such as races and nations.

Entities:  

Year:  2003        PMID: 15618720     DOI: 10.2133/dmpk.18.71

Source DB:  PubMed          Journal:  Drug Metab Pharmacokinet        ISSN: 1347-4367            Impact factor:   3.614


  1 in total

1.  Potential factors for inadequate voriconazole plasma concentrations in intensive care unit patients and patients with hematological malignancies.

Authors:  Martin Hoenigl; Wiebke Duettmann; Reinhard B Raggam; Katharina Seeber; Katharina Troppan; Sonja Fruhwald; Florian Prueller; Jasmin Wagner; Thomas Valentin; Ines Zollner-Schwetz; Albert Wölfler; Robert Krause
Journal:  Antimicrob Agents Chemother       Date:  2013-04-29       Impact factor: 5.191

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.